Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug619 | COVID 19 Diagnostic Test Wiki | 0.41 |
| drug1243 | Exercise training group Wiki | 0.41 |
| drug1865 | Lopinavir/ Ritonavir Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug701 | CYNK-001 Wiki | 0.41 |
| drug530 | Blood tests sputum, nasal lavage and brushing Wiki | 0.41 |
| drug1867 | Lopinavir/ Ritonavir Placebo Wiki | 0.41 |
| drug1304 | Favipiravir Placebo Wiki | 0.29 |
| drug3433 | Tezepelumab Wiki | 0.29 |
| drug954 | Cyclosporine Wiki | 0.18 |
| drug1296 | Favipiravir Wiki | 0.09 |
| drug2505 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001982 | Bronchial Diseases NIH | 0.41 |
| D006969 | Hypersensitivity, Immediate NIH | 0.41 |
| D012130 | Respiratory Hypersensitivity NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006453 | Hemoglobinopathies NIH | 0.41 |
| D030341 | Nidovirales Infections NIH | 0.29 |
| D001249 | Asthma NIH | 0.20 |
| D006967 | Hypersensitivity, NIH | 0.18 |
| D003333 | Coronaviridae Infections NIH | 0.18 |
| D008171 | Lung Diseases, NIH | 0.18 |
| D012140 | Respiratory Tract Diseases NIH | 0.17 |
| D012327 | RNA Virus Infections NIH | 0.17 |
| D051436 | Renal Insufficiency, Chronic NIH | 0.14 |
| D007674 | Kidney Diseases NIH | 0.12 |
| D008173 | Lung Diseases, Obstructive NIH | 0.11 |
| D002908 | Chronic Disease NIH | 0.11 |
| D007249 | Inflammation NIH | 0.07 |
| D012141 | Respiratory Tract Infections NIH | 0.07 |
| D011024 | Pneumonia, Viral NIH | 0.05 |
| D014777 | Virus Diseases NIH | 0.04 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D011014 | Pneumonia NIH | 0.02 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002099 | Asthma HPO | 0.20 |
| HP:0002088 | Abnormal lung morphology HPO | 0.19 |
| HP:0012393 | Allergy HPO | 0.18 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012622 | Chronic kidney disease HPO | 0.17 |
| HP:0000077 | Abnormality of the kidney HPO | 0.14 |
| HP:0006536 | Pulmonary obstruction HPO | 0.13 |
| HP:0011947 | Respiratory tract infection HPO | 0.08 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 6 clinical trials
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
Description: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.
Measure: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies. Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
Description: Number and severity of adverse events
Measure: Phase 1: Frequency and Severity of Adverse Events (AE) Time: Up to 6 monthsDescription: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR
Measure: Phase 1: Rate of clearance of SARS-CoV-2 Time: Up to 6 monthsDescription: Proportion of subjects who improved clinical symptoms related to lower respiratory tract infection, as measured by National Early Warning Score 2 (NEWS2) score.
Measure: Phase 1: Rate of clinical improvement Time: Up to 6 monthsDescription: Time from the date of randomization to the clearance of SARS-CoV-2 by rRT-PCR. Negative results will need to be confirmed by a second negative result in the same sample type at least 24 hours after the first negative result.
Measure: Phase 2: Time to Clearance of SARS-CoV-2 Time: Up to 28 daysDescription: Time from the date of randomization to the first date of improved clinical symptoms related to lower respiratory tract infection. Improvement as measured by National Early Warning Score 2 (NEWS2) Score.
Measure: Phase 2: Time to Clinical Improvement by NEWS2 Score Time: Up to 28 daysDescription: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR
Measure: Rate of Clearance of SARS-CoV-2 Time: Up to 6 monthsDescription: Number and severity of adverse events
Measure: Phase 2: Frequency and Severity of Adverse Events (AE) Time: up to 6 monthsDescription: Time to medical discharge as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by time to medical discharge Time: up to 6 monthsDescription: Hospital utilization will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by hospital utilization Time: up to 6 monthsDescription: Mortality rate will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by measuring mortality rate Time: up to 6 monthsDescription: Assess the impact of CYNK-001 on changes in sequential organ failure assessment (SOFA) score.
Measure: Impact of CYNK-001 on sequential organ failure assessment (SOFA) score Time: Up to 28 daysDescription: Time from randomization to the date of disappearance of virus from lower respiratory tract infection (LRTI) specimen where it has previously been found (induced sputum, endotracheal aspirate).
Measure: Time to Pulmonary Clearance Time: Up to 28 daysDescription: For ventilatory support subjects, the days with supplemental oxygen-free.
Measure: Supplemental oxygen-free days Time: Up to 28 daysDescription: Proportion of subjects who need invasive or non-invasive ventilation
Measure: Proportion of subjects requiring ventilation Time: Up to 28 daysSARS-CoV-2 outbreak causes a spectrum of clinical patterns that varies from asymptomatic infection to mildly symptomatic manifestations and more-severe forms that need intensive care. Until now, the immune response to SARS-CoV-2 virus infection has been poorly reported to help decision for immune modulation therapies. As a consequence, trials have been designed to test both anti-inflammatory molecules as steroids or anti-bodies against IL-6, and others proposing to "boost" immunity with interferon beta based on similar inclusion criteria. The immune response to infective agents including viruses may have a complex time evolution with early and late phases corresponding to different patterns, oscillating between pro-inflammation and immune-depression. The potential window to improve outcome in COVID-19 by therapeutic intervention aimed at a fine tuning between immune toxicity and immunodepression requires a longitudinal assessment during the course of illness, especially for the patients who develop acute respiratory failure. Immune monitoring of both innate and adaptive immunity would then be essential to appropriately design clinical trials. The whole blood cells evaluation was recorded according to the time intervals between the onset of symptoms and the sampling after ICU admission. Patients' care was standardized, especially with regard to ventilation, sedation, and antimicrobial treatment. In this study the investigators prospectively perform a longitudinal study of both innate and adaptive immunity on patients admitted to ICU for an COVID-19 related acute respiratory failure. The data will be analyzed in reference to the onset of initial symptoms and also to the admission in ICU. The primary end point is the evolution of the characterization of monocytes and their subsets in term of number and expression of HLA-DR. A similar approach is used for lymphocytes and their subtypes with in addition, an ex vivo testing of their capabilities to be stimulated by SARS-CoV-2 viral proteins in term of TNFalpha, INFgamma, and IL1beta production. The secondary end-point was to test the association with outcomes and other non-specific markers of inflammation as CRP (C reactive protein), PCT (procalcitonin), DDimers and ferritin.
Description: circulating immune cell characterization
Measure: Changes in monocytes HLA-DR expression Time: through ICU stay, an average of 30 daysDescription: circulating immune cell characterization
Measure: Changes in lymphocytes subpopulations numbers Time: through ICU stay, an average of 30 daysDescription: circulating immune cell characterization
Measure: Changes in monocytes number Time: through ICU stay, an average of 30 daysDescription: stimulation by SARS-CoV-2 viral proteins
Measure: TNFalpha level Time: 4 hoursDescription: stimulation by SARS-CoV-2 viral proteins
Measure: INFgamma level Time: 4 hoursDescription: stimulation by SARS-CoV-2 viral proteins
Measure: IL1beta level Time: 4 hoursDescription: Sequential Organ dysfunction assessement, ranging from 0 (better) to 24 (worst) outcome
Measure: SOFA score Time: through ICU stay, an average of 30 daysDescription: mortality
Measure: number of recorded deaths Time: through study completion, an average of 6 monthsDescription: infectious complications
Measure: presence of pneumonia Time: through ICU stay, an average of 30 daysDescription: infectious complications
Measure: presence of bacteremia Time: through ICU stay, an average of 30 daysDescription: infectious complications
Measure: presence of urinary tract infection Time: through ICU stay, an average of 30 daysDescription: inflammation marker
Measure: C reactive protein Time: through ICU stay, an average of 30 daysDescription: inflammation marker
Measure: D Dimers Time: through ICU stay, an average of 30 daysDESIGN Longitudinal prospective observational multicentre study. Primary objective: Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung disease
Description: Anti-viral cytokine protein concentration in blood samples by ELISA
Measure: Anti-viral cytokine levels in blood samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Inflammatory cytokine protein concentration in sputum samples by ELISA
Measure: Anti-viral cytokines profiles within sputum samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Inflammatory cytokine protein concentration in nasal lavage samples by ELISA
Measure: Anti-viral cytokine profiles within nasal lavage samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Inflammatory gene expression in upper airway respiratory epithelial cells by RNA sequencing.
Measure: Expression of inflammatory gene expression in upper respiratory epithelial airway cells using nasal brush specimens in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of viral components recognized by the adaptive immune system
Measure: Identify the T cell antigens and B cell epitopes in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Cytokine protein concentration following PBMC stimulation to pathogen recognition receptor agonists by Elispot
Measure: Peripheral blood mononuclear cell (PBMC) interferon mediated immune responses to pathogen recognition receptor agonists in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of endothelial function
Measure: Identify endothelial function in chronic respiratory disease associated with susceptibility to severe COVID-19 infection using EndoPAT testing Time: Through study completion an average of 1 yearDescription: Serum and plasma protein concentration of endothelial cell inflammation biomarkers by ELISA
Measure: Endothelial cell inflammation biomarkers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of sputum microbiome
Measure: Identify sputum 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Analysis of nasal microbiome
Measure: Identify nasal lavage 16S rRNA and ITS sequences in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearDescription: Study participant survey
Measure: Identify quality of life markers in chronic respiratory disease associated with susceptibility to severe COVID-19 infection Time: Through study completion an average of 1 yearNew York City (NYC) has become the epicenter of the worldwide pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). By collecting and summarizing the experience with other major health care providers in the tristate (New York (NY), New Jersey (NJ) and Connecticut (CT)) are, the investigators are uniquely positioned to inform the rest of the country about what to expect and how to manage children and young adults with hematological, oncological or stem cell transplant diagnoses during the pandemic.
Description: To measure the success of the data registry in how many patients agreed to participate and completed the one year follow up. A confirmed case of COVID-19 is defined as a positive result on a reverse-transcriptase- polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab, or a serum antibody test. Only laboratory-confirmed cases will be described as positive.
Measure: Number of tristate area pediatric HOT patients tested for COVID-19 that completed 1 year follow-up Time: One yearDescription: To analyze effect of COVID-19 on patients and their families mental health. PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression.
Measure: Change in PROMIS T-score Time: Baseline, 3 Months, 6 MonthsDescription: To examine if the pandemic has effects on the patients' nutrition and microbiome. Each patient is given an opportunity to provide stool samples in addition to survey response.
Measure: Number of collected and analyzed stool samples Time: Up to one yearData show that the coronavirus disease 2019 (COVID-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. In addition, the prevalence of chronic diseases among adolescents has increased in the last years. About 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. In march, 2020, the quarantine was officially implemented in Sao Paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. To mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.
Description: Semi structured interview
Measure: Safety and efficacy of a home-based exercise training program Time: From baseline to 3 months of follow-upDescription: Semi structured interview
Measure: Patients perceptions during social isolation Time: From baseline to 3 months of follow-upDescription: Quality of life will be assessed by means of Pediatric Quality of Life inventory (PedsQLTM 4.0)
Measure: Adolescents quality of life Time: From baseline to 3 months of follow-upDescription: Will be assessed by means of a visual analog scale (from 0 - no disease activity) to 10 - maximum disease activity).
Measure: Disease activity Time: From baseline to 3 months of follow-upDescription: Will be assessed using the visual analog scale from 0 (very good condition) to 10 (very poor condition).
Measure: Disease overall assessment Time: From baseline to 3 months of follow-upDescription: Will be assessed by means of Strengths & Difficulties Questionnaires
Measure: Strengths and difficulties Time: From baseline to 3 months of follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports